Latest & greatest articles for trazodone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on trazodone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on trazodone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for trazodone

1. Trazodone

Trazodone Top results for trazodone - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for trazodone The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

2. Comparative risk of harm associated with trazodone or atypical antipsychotic use in older adults with dementia: a retrospective cohort study Full Text available with Trip Pro

Comparative risk of harm associated with trazodone or atypical antipsychotic use in older adults with dementia: a retrospective cohort study Trazodone is increasingly prescribed for behavioural and psychological symptoms of dementia, but little is known about its risk of harm. Our objective was to describe the comparative risk of falls and fractures among older adults with dementia dispensed trazodone or atypical antipsychotics.The study cohort included adults with dementia (excluding patients (...) with chronic psychotic illnesses) living in long-term care and aged 66 years and older. Data were obtained from routinely collected, linked health administrative databases in Ontario, Canada. We compared new users of trazodone with new users of atypical antipsychotics (quetiapine, olanzapine or risperidone) between Dec. 1, 2009, and Dec. 31, 2015. The primary outcome was a composite of fall or major osteoporotic fracture within 90 days of first prescription. Secondary outcomes were falls, major

2019 EvidenceUpdates

3. Trazodone/Gabapentin Fixed Dose Combination Products in Painful Diabetic Neuropathy

Trazodone/Gabapentin Fixed Dose Combination Products in Painful Diabetic Neuropathy Trazodone/Gabapentin Fixed Dose Combination Products in Painful Diabetic Neuropathy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Trazodone/Gabapentin Fixed Dose Combination Products in Painful Diabetic Neuropathy The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03749642 Recruitment Status : Recruiting First Posted : November 21, 2018

2018 Clinical Trials

4. Low-Dose Trazodone, Benzodiazepines, and Fall-Related Injuries in Nursing Homes: A Matched-Cohort Study (Abstract)

Low-Dose Trazodone, Benzodiazepines, and Fall-Related Injuries in Nursing Homes: A Matched-Cohort Study To evaluate whether risk of fall-related injuries differs between nursing home (NH) residents newly dispensed low-dose trazodone and those newly dispensed benzodiazepines.Retrospective, matched cohort study in linked, population-based administrative data. Matching was based on propensity score ( ± 0.2 standard deviations of the score as a caliper), age ( ± 1 year), sex, frailty status (...) functions accounted for competing risk of death. Sensitivity analyses were used to examine falls resulting in hip or wrist fracture only, as well as different lengths of follow-up at 30, 60, and 180 days.Cumulative incidence of a fall-related injury in the 90 days after index was 5.7% for low-dose trazodone users and 6.0% for benzodiazepine users (between-group change=-0.29, 95% confidence interval (CI)=-1.02-0.44]; hazard ratio=0.94, 95% CI=0.83-1.08). Findings were consistent across sensitivity

2018 EvidenceUpdates

5. Trazodone use and risk of dementia: A population-based cohort study. Full Text available with Trip Pro

Trazodone use and risk of dementia: A population-based cohort study. In vitro and animal studies have suggested that trazodone, a licensed antidepressant, may protect against dementia. However, no studies have been conducted to assess the effect of trazodone on dementia in humans. This electronic health records study assessed the association between trazodone use and the risk of developing dementia in clinical practice.The Health Improvement Network (THIN), an archive of anonymised medical (...) and prescribing records from primary care practices in the United Kingdom, contains records of over 15 million patients. We assessed patients from THIN aged ≥50 years who received at least two consecutive prescriptions for an antidepressant between January 2000 and January 2017. We compared the risk of dementia among patients who were prescribed trazodone to that of patients with similar baseline characteristics prescribed other antidepressants, using a Cox regression model with 1:5 propensity score matching

2019 PLoS medicine

6. Trazodone for agitation in dementia. Full Text available with Trip Pro

Trazodone for agitation in dementia. Behavioural and psychiatric disturbances affect at least 50% of people with Alzheimer's disease and other dementias. Neuroleptic drugs are extensively prescribed to treat behavioural manifestations of dementia in spite of only modest efficacy and a high frequency of adverse effects. There is clearly a need for safer and more effective remedies. Trazodone is a psychoactive compound with sedative and antidepressant properties, and with mixed serotonin agonist (...) and antagonist effects. Functional serotonergic deficits may be related to the genesis of behavioural disturbances in dementia.To determine the clinical efficacy and safety of trazodone, for any type of behavioural or psychological cognition in people with dementia without an additional diagnosis of depression.Trials were identified from a search of the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group on 1 June 2004 using the terms trazodon*, beneficat, desirel, sideril, trazodil

2004 Cochrane

7. Efficacy and Safety of Risperidone and Trazodone Monotherapy and Combination Therapy in Critically Ill Patients With Delirium

Efficacy and Safety of Risperidone and Trazodone Monotherapy and Combination Therapy in Critically Ill Patients With Delirium Efficacy and Safety of Risperidone and Trazodone Monotherapy and Combination Therapy in Critically Ill Patients With Delirium - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached (...) the maximum number of saved studies (100). Please remove one or more studies before adding more. Efficacy and Safety of Risperidone and Trazodone Monotherapy and Combination Therapy in Critically Ill Patients With Delirium The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02118688 Recruitment Status

2014 Clinical Trials

8. Trazodone

Trazodone USE OF TRAZODONE IN PREGNANCY 0344 892 0909 USE OF TRAZODONE IN PREGNANCY (Date of issue: March 2018 , Version: 3 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Trazodone is a triazolopyridine antidepressant drug used in the treatment (...) of anxiety and depressive disorders, particularly where sedation is required. Data are limited to a very small number of trazodone-exposed pregnant women and providing an estimate on the likelihood of adverse outcomes following exposure during pregnancy is not currently possible. However, there is currently no evidence to suggest that exposure to trazodone is associated with an increased risk of congenital malformation, spontaneous abortion or stillbirth/intrauterine death, preterm delivery or low infant

2014 UK Teratology Information Service

9. [Combination of buprenorphine and trazodone in preanesthetic medication]. (Abstract)

[Combination of buprenorphine and trazodone in preanesthetic medication]. 3614688 1987 08 28 2013 11 21 0375-9393 53 1-2 1987 Jan-Feb Minerva anestesiologica Minerva Anestesiol [Combination of buprenorphine and trazodone in preanesthetic medication]. 1-8 Santamaria L B LB Sinardi A U AU Sutera T T Latella S S De Pasquale M M De Leo S S Mandolfino T T ita Clinical Trial Comparative Study English Abstract Journal Article Randomized Controlled Trial Associazione buprenorfina-trazodone (...) in preanestesia. Italy Minerva Anestesiol 0375272 0375-9393 40D3SCR4GZ Buprenorphine YBK48BXK30 Trazodone IM Abdomen surgery Adult Aged Buprenorphine Female Humans Male Middle Aged Preanesthetic Medication Trazodone 1987 1 1 1987 1 1 0 1 1987 1 1 0 0 ppublish 3614688

1987 Minerva anestesiologica Controlled trial quality: uncertain

10. Evaluation of Trazodone and Quetiapine for Insomnia: An Observational Study in Psychiatric Inpatients Full Text available with Trip Pro

Evaluation of Trazodone and Quetiapine for Insomnia: An Observational Study in Psychiatric Inpatients Insomnia is symptomatic of most psychiatric disorders. Non-habit-forming agents such as trazodone and quetiapine are commonly used off-label to treat patients with insomnia. The safety and efficacy of trazodone and quetiapine as medications for treatment of insomnia have never been directly contrasted. The objective of this study was to compare the effectiveness of trazodone to quetiapine among (...) inpatient psychiatric patients by measuring the traditional sleep parameters of total sleep time, number of nighttime awakenings, sleep efficiency, sleep latency, length of hospitalization, and patient-reported side effects.Participants were recruited from St Helena Hospital Center for Behavioral Health, Vallejo, California. Patient inclusion criteria were age 18 to 65 years, admitted between September 2011 and February 2012, and a physician order for trazodone or quetiapine for insomnia. Exclusion

2013 The Primary Care Companion for CNS Disorders

11. Accuracy and Efficacy of Trazodone (Desyrel) on Sleep Quality and Pain Management of TMD Patient

Accuracy and Efficacy of Trazodone (Desyrel) on Sleep Quality and Pain Management of TMD Patient Accuracy and Efficacy of Trazodone (Desyrel) on Sleep Quality and Pain Management of TMD Patient - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Accuracy and Efficacy of Trazodone (Desyrel) on Sleep Quality and Pain Management of TMD Patient The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03522207 Recruitment Status : Recruiting

2018 Clinical Trials

12. Acute Liver Failure due to Trazodone and Diazepam Full Text available with Trip Pro

Acute Liver Failure due to Trazodone and Diazepam Most antidepressant agents have the potential to cause liver injury, even at therapeutic doses. Nevertheless, drug-induced liver injury (DILI) from antidepressant agents is a rare event. There is no way to prevent idiopathic DILI, but the severity of the reaction may be minimized with prompt recognition and early withdrawal of the agent. We describe a rare case of a 63-year-old man presenting with acute liver failure after 3 months of trazodone (...) and diazepam administration at normal therapeutic doses, requiring liver transplantation. This report should increase physicians' awareness of this complication and call attention to the regular monitoring of liver tests in patients taking trazodone, in order to prevent life-threatening complications.

2016 GE Portuguese journal of gastroenterology

13. Effects of trazodone on insomnia and anxiety in depressed patients: a clinical and sleep EEG study. (Abstract)

Effects of trazodone on insomnia and anxiety in depressed patients: a clinical and sleep EEG study. Clinical and sleep EEG effects of trazodone in major depression were investigated using a 5-week single-blind study design. Nine patients with DSM-N major depression were selected. Trazodone (50-250 mg) was given following a 2-week placebo run-in period. Both sleep and psychiatric evaluations were performed at different time points. Early and persistent sleep-inducing effects were detected (...) , including the improvement of objective insomnia features and increased amounts of slow wave sleep. However, no significant changes of REM sleep measures were found. The sleep EEG changes seem to be related to the clinical improvement of both anxiety and insomnia, but there is no apparent relationship with the antidepressant action, which occurs at a later stage of the treatment. Trazodone may be useful in depressed patients, either as a hypnotic-like agent or as an effective antidepressant drug

1997 International journal of psychiatry in clinical practice Controlled trial quality: uncertain

14. Pharmacokinetics, bioavailability, and hemodynamic effects of trazodone after intravenous and oral administration of a single dose to dogs. (Abstract)

Pharmacokinetics, bioavailability, and hemodynamic effects of trazodone after intravenous and oral administration of a single dose to dogs. To determine the pharmacokinetics and hemodynamic effects of trazodone after IV and oral administration in dogs and bioavailability after oral administration.6 adult Beagles.Dogs received trazodone HCl (8 mg/kg) orally and IV in a randomized controlled crossover design. Blood samples were collected at various times after administration. Heart rates (...) and indirectly measured blood pressures of dogs and plasma concentrations and pharmacokinetics of trazodone were determined.Following IV administration, the mean ± SD elimination half-life, apparent volume of distribution, and plasma total body clearance were 169 ± 53 minutes, 2.53 ± 0.47 L/kg, and 11.15 ± 3.56 mL/min/kg, respectively. Following oral administration, the mean ± SD elimination half-life and absolute bioavailability were 166 ± 47 minutes and 84.6 ± 13.2%, respectively. Maximum plasma

2013 American journal of veterinary research Controlled trial quality: uncertain

15. Trazodone--a comparison of single night-time and divided daily dosage regimens. (Abstract)

Trazodone--a comparison of single night-time and divided daily dosage regimens. The antidepressant efficacy, influence on sleep variables and incidence of side-effects of trazodone (100-400 mg daily), given either as a single night-time dose or thrice daily, were compared in a double-blind, 4 week, parallel group, multicentre hospital study. Of 56 patients who entered the study, full data was available for 37, of whom 20 took the medication at night and the other 17 received divided doses (...) during the day. The results showed equivalent therapeutic efficacy for the two dosage regimens and tolerance was good in both groups. For onset and also duration of sleep, significantly more patients in the single night-time group improved than worsened in response. Both groups of patients tended to report a more satisfying sleep and greater freshness on waking, although these latter effects were not statistically significant. For the group taking trazodone thrice daily, there was a trend for more

1984 Psychopharmacology Controlled trial quality: uncertain

16. Trazodone: alternative dose regimens and sleep. (Abstract)

Trazodone: alternative dose regimens and sleep. In a double-blind trial, 146 depressed patients were allocated at random to treatment with the same daily dose (100 mg to 150 mg) of trazodone administered either as divided doses twice daily or as a single dose at night. Over the trial period of 6 weeks there was a highly significant reduction in the mean Hamilton Depression Rating Scale scores in both treatment groups, with no significant differences between them. The patients completed 10 (...) . Trazodone administered as a single dose at night or when given in twice daily divided dosage, improved sleep. During the first week this effect was significantly better for the single dose at night group. This early effect may be particularly useful in providing psychological encouragement to depressed patients at the onset of treatment.

1984 Pharmatherapeutica Controlled trial quality: uncertain

17. Increased deep sleep after trazodone use: a double-blind placebo-controlled study in healthy young adults. (Abstract)

Increased deep sleep after trazodone use: a double-blind placebo-controlled study in healthy young adults. The effects of trazodone on sleep were compared with those of placebo and the sedating tricyclic antidepressant trimipramine in a double-blind crossover study in six healthy young men. Only trazodone significantly increased deep sleep without otherwise altering the normal architecture of sleep. The alpha-adrenergic receptor-blocking property of trazodone and a relative lack

1990 Journal of Clinical Psychiatry Controlled trial quality: uncertain

18. Sentra PM (a Medical Food) and Trazodone in the Management of Sleep Disorders. Full Text available with Trip Pro

Sentra PM (a Medical Food) and Trazodone in the Management of Sleep Disorders. Sleep disorders are a common and poorly treated disease state. This double blind, four arm placebo-controlled, randomized trial compared (1) low dose trazodone, (2) Sentra PM, a neurotransmitter based medical food, (3) the joint administration of trazodone and the medical food Sentra PM and (4) placebo. There were 111 subjects studied in 12 independent sites. Subjects underwent baseline screening, informed consent (...) for the Sentra PM and combination of Sentra PM and trazodone (-41 and -56 minutes P < 0.001). There was an improvement in quality of sleep for the amino acid formulation Sentra PM and the combination (3.86 and 6.48 Likert units on a 10 point scale P < 0.001). There was an activation of circadian activity percent at night in the medical food and combination groups while there was no change in parasympathetic activity in either the placebo or trazodone group. These data indicate that Sentra PM can improve

2012 Journal of central nervous system disease Controlled trial quality: predicted high

19. Trazodone for antidepressant-associated insomnia. (Abstract)

Trazodone for antidepressant-associated insomnia. The authors investigated trazodone as a hypnotic for depressed patients who had persistent, exacerbated, or new insomnia while taking either fluoxetine or bupropion.Seventeen depressed patients who had insomnia while taking fluoxetine or bupropion were given either trazodone or placebo in a double-blind crossover trial. Sleep was assessed by self-report with the Pittsburgh Sleep Quality Index and the sleep items of the Yale-New Haven Hospital (...) Depressive Symptom Inventory.Improvement with trazodone, but not with placebo, was shown by the total Pittsburgh index scores and Yale-New Haven inventory total sleep scores and by the Pittsburgh index measures of sleep duration and Yale-New Haven inventory measures of early morning awakening, and there was a trend toward improvement in the Yale-New Haven inventory item regarding middle of the night awakenings. Subjective sleep quality and sleep latency also showed a trend toward improvement

1994 American Journal of Psychiatry Controlled trial quality: uncertain

20. Changes in EEG power density of non-REM sleep in depressed patients during treatment with trazodone. (Abstract)

Changes in EEG power density of non-REM sleep in depressed patients during treatment with trazodone. Recently, it was hypothesized that acute or cumulative suppression of non-REM sleep intensity might be related to the therapeutic effects of antidepressants. This intensity has been proposed to be expressed in the EEG power density in non-REM sleep. In the present study, the relationship was examined between the changes of EEG power density in non-REM sleep and the changes in clinical state in 8 (...) depressed patients during treatment with trazodone. A 1-week wash-out period was followed by 1 week of placebo administration, a medication period of 5 weeks and a 1-week placebo period. To minimize systematic influences of sleep duration and non-REM-REM sleep alterations, EEG power was measured over the longest common amount of non-REM sleep stages 2-4 (168.5 min), accumulated from sleep onset onwards. During trazodone treatment, the 13- and 14-Hz bins showed a significant reduction in EEG power

1995 Journal of Affective Disorders Controlled trial quality: uncertain